Milestone Pharmaceuticals Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Milestone Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-12-31 was 15.01K shares.
- Milestone Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-09-30 was 0.00 shares.
- Milestone Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Milestone Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-03-31 was 18.15K shares, a 51.82% decline year-over-year.
- Milestone Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2019 was 33.16K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2019-12-31 | 15.01K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-10-23 | 33.16K shares 10-K/A · filed 2020-10-23 |
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | |
| 2019-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | |
| 2019-03-31 | 18.15K shares 10-Q · filed 2019-06-19 | |
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | |
| 2018-06-30 | 5.11K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | |
| 2018-03-31 | 37.67K shares 10-Q · filed 2019-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |